Clinical Guidelines

The Strategic Role of CRA AI Agents in Clinical Research

Using agentic AI to reduce clinical trial inefficiency

Share

The complexity and inefficiencies of clinical trials are leading to significant delays in the approval of new therapies, with trial cycle times increasing while clinical trial durations shorten. Agentic AI has the potential to resolve these inefficiencies by automating tasks such as data management and site monitoring, thus allowing clinical research associates (CRAs) to concentrate on higher-value tasks. This partnership between AI and CRAs is crucial for enhancing productivity in drug development processes, ultimately accelerating patient access to new therapies.

Original Source(s)

The Strategic Role of CRA AI Agents in Clinical Research

Using agentic AI to reduce clinical trial inefficiency

  • by Andrew Mackinnon

  • March 6, 2026

  • 9 min

Related Content

Business-in-Brief: February 2026

This month’s analytical science business news: seed funding, strategic partnerships, and a surge of genomics and mass spec launches

  • March 5, 2026

  • 3 min
Shining a Light into the ADC Conjugation Black Box

A multi-year hunt for a “Goldilocks salt” paved the way for HIC-MS coupling and real-time ADC reaction monitoring

Innovations Shaping Women’s Cancer Care in 2026

As we move through 2026, new technologies and refined surgical techniques are transforming outcomes for women facing cancer diagnoses.

  • by

  • March 4, 2026

  • 6 min